Description
Anti-RELP Antibody, Non-Fucosylated (BioBet-1576ZP) is a human monoclonal IgG antibody against RELP. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced RELP antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
REG4
Full Name
Reg Like Protein
Background
regenerating islet-derived family, member 4
Alternative Names
REG4; regenerating islet-derived family, member 4; GISP; RELP; REG-IV; regenerating islet-derived protein 4; REG-4; reg IV; REG-like protein; regenerating gene type IV; gastrointestinal secretory protein; regenerating islet-derived protein IV;
Gene ID
83998
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with REG4 include Ulcerative Colitis and Pseudomyxoma Peritonei.
Related Pathways
Its related pathways are Gastric cancer and Adhesion.
Function
Lectin that does not depend on calcium, shows mannose binding specificity, and can maintain carbohydrate recognition activity in an acidic environment. May be involved in the inflammation and metaplasia of the gastrointestinal epithelium.
Post-translational modifications
1.Glycosylation at Asn50 2.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-1576ZP
Description
The novel anti-RELP fusion antibody target provides a method for modulating or treating at least one RELP protein related disease, such as leukemia, lymphoma, carcinoma, solid tumors.
Antibody Indication
Cancer
